Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus

Empagliflozin confers reno‐protection in acute myocardial infarction and type 2 diabetes mellitus

Abstract Aims Although the reno‐protective effects of sodium–glucose cotransporter 2 inhibitors are known in patients with heart failure or type 2 diabetes mellitus (T2DM), this effect has not been confirmed in patients with acute myocardial infarction (AMI). Methods and results The prospective, mul...

Full description

Bibliographic Details
Main Authors:	Kosuke Mozawa, Yoshiaki Kubota, Yu Hoshika, Shuhei Tara, Yukichi Tokita, Kenji Yodogawa, Yu‐ki Iwasaki, Takeshi Yamamoto, Hitoshi Takano, Yayoi Tsukada, Kuniya Asai, Masaaki Miyamoto, Yasushi Miyauchi, Eitaro Kodani, Mitsunori Maruyama, Jun Tanabe, Wataru Shimizu
Format:	Article
Language:	English
Published:	Wiley 2021-10-01
Series:	ESC Heart Failure
Subjects:	Acute myocardial infarction Empagliflozin Estimated glomerular filtration rate Sodium–glucose cotransporter 2 inhibitor Type 2 diabetes mellitus Uric acid
Online Access:	https://doi.org/10.1002/ehf2.13509

Similar Items

Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
by: Wataru Shimizu, et al.
Published: (2020-09-01)

Euglycemic Diabetic Ketoacidosis after a Single Dose of Empagliflozin in a Patient with Pancreatitis
by: Marta Brandão Calçada, et al.
Published: (2021-04-01)

Early detection of euglycemic ketoacidosis during thoracic surgery associated with empagliflozin in a patient with type 2 diabetes: A case report
by: Chie Kitahara, et al.
Published: (2021-04-01)

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure
by: Nikole J. Byrne, BSc, et al.
Published: (2017-08-01)

Empagliflozin Contributes to Polyuria via Regulation of Sodium Transporters and Water Channels in Diabetic Rat Kidneys
by: Sungjin Chung, et al.
Published: (2019-03-01)

Empagliflozin in Patients With Heart Failure: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Deng Pan, et al.
Published: (2021-06-01)

Empagliflozin improves cardiac function in heart failure with reduced ejection fraction independent of loading conditions
by: Bo Liang, et al.
Published: (2020-03-01)

Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
by: Yihai Liu, et al.
Published: (2021-01-01)

Cost‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure
by: Odette S. Reifsnider, et al.
Published: (2020-12-01)

Comparison of the changes in the factors associated with the renal prognosis of non-elderly and elderly subjects treated with empagliflozin- a retrospective observation study in Japanese patients with type 2 diabetes
by: Ito H, et al.
Published: (2019-09-01)

Combination therapy in type 2 diabetes mellitus: adding empagliflozin to basal insulin
by: Andrew Ahmann
Published: (2015-11-01)

Empagliflozin and Liraglutide Differentially Modulate Cardiac Metabolism in Diabetic Cardiomyopathy in Rats
by: Nguyen Ngoc Trang, et al.
Published: (2021-01-01)

Empagliflozin on top of metformin treatment improves arterial function in patients with type 1 diabetes mellitus
by: Mojca Lunder, et al.
Published: (2018-12-01)

Sodium-glucose cotransporter 2 inhibitors with insulin in type 2 diabetes: Clinical perspectives
by: Mathew John, et al.
Published: (2016-01-01)

Effect of metformin and empagliflozin on adiponectin and leptin levels in rat model of hypo- and hyperthyroidism
by: Desimira Mironova, et al.
Published: (2021-01-01)

Effects of liraglutide and empagliflozin added to insulin therapy in patients with type 2 diabetes: A randomized controlled study
by: Hirotatsu Nakaguchi, et al.
Published: (2020-11-01)

Empagliflozin in type 1 diabetes
by: Mathieu C, et al.
Published: (2019-08-01)

Secondary analyses to assess the profound effects of empagliflozin on endothelial function in patients with type 2 diabetes and established cardiovascular diseases: The placebo‐controlled double‐blind randomized effect of empagliflozin on endothelial function in cardiovascular high risk diabetes mellitus: Multi‐center placebo‐controlled double‐blind randomized trial
by: Atsushi Tanaka, et al.
Published: (2020-11-01)

A NEW INDICATION FOR EMPAGLIFLOZIN: TURNING POINT IN THE TREATMENT OF TYPE 2 DIABETES
by: M. V. Amosova, et al.
Published: (2017-12-01)

Empagliflozin and the Prevention of Heart Failure
by: Douglas L. Mann, MD, et al.
Published: (2017-08-01)

Cardiovascular effects of sodium glucose cotransporter 2 inhibitors
by: Santos Cavaiola T, et al.
Published: (2018-04-01)

Stability-indicating HPLC-DAD method for the determination of empagliflozin
by: Shilpi Pathak, et al.
Published: (2021-08-01)

[Budget impact analysis of empagliflozin for the treatment of type 2 diabetes in Italy]
by: Sergio Iannazzo, et al.
Published: (2016-03-01)

Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial
by: Atsushi Tanaka, et al.
Published: (2017-04-01)

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission
by: Hao Zhou, et al.
Published: (2018-05-01)

Characteristics of Ventricular Electrophysiological Substrates in Metabolic Mice Treated with Empagliflozin
by: Shih-Jie Jhuo, et al.
Published: (2021-06-01)

Early administration of empagliflozin preserved heart function in cardiorenal syndrome in rat
by: Chih-Chao Yang, et al.
Published: (2019-01-01)

Empagliflozin: a new strategy for nephroprotection in diabetes
by: Anton Ivanovich Korbut, et al.
Published: (2017-05-01)

The Sodium-Glucose Co-Transporter 2 Inhibitor, Empagliflozin, Protects against Diabetic Cardiomyopathy by Inhibition of the Endoplasmic Reticulum Stress Pathway
by: Yang Zhou, et al.
Published: (2017-05-01)

Spotlight on empagliflozin/metformin fixed-dose combination for the treatment of type 2 diabetes: a systematic review
by: Kedia R, et al.
Published: (2016-09-01)

Efficacy and Safety of Empagliflozin Continuation in Patients with Type 2 Diabetes Hospitalised for Acute Decompensated Heart Failure
by: Luis M. Pérez-Belmonte, et al.
Published: (2021-08-01)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
by: Moritz Mahling, et al.
Published: (2019-08-01)

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure
by: Reed JW
Published: (2016-10-01)

Early benefits of empagliflozin in patients with or without heart failure: findings from EMPA‐REG OUTCOME
by: Pierpaolo Pellicori, et al.
Published: (2020-12-01)

Empagliflozin Alleviates Atherosclerosis Progression by Inhibiting Inflammation and Sympathetic Activity in a Normoglycemic Mouse Model
by: Liu Y, et al.
Published: (2021-05-01)

The effect of empagliflozin on the development of chronic heart failure after myocardial infarction according to a 12-month prospective study
by: Alexey A. Nekrasov, et al.
Published: (2019-10-01)

Empagliflozin inhibits Na+/H+ exchanger activity in human atrial cardiomyocytes
by: Maximilian Trum, et al.
Published: (2020-12-01)

Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA‐REG OUTCOME trial
by: Subodh Verma, et al.
Published: (2021-08-01)

Empagliflozin Effectively Attenuates Olanzapine-Induced Body Weight Gain in Female Wistar Rats
by: Ghulam Md Ashraf, et al.
Published: (2021-04-01)

Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes
by: Munir KM, et al.
Published: (2016-04-01)